Activity of sorafenib (SOR) in patients (pts) with imatinib (IM) and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST): a phase II trial of the University of Chicago Phase II Consortium

Authors
Category Primary study
Journal2008 ASCO annual meeting
Year 2008
This article has no abstract
Epistemonikos ID: 7967a89792874f7ca002cf69d3be29078c85bc36
First added on: Oct 30, 2016